All In Biotech

Drug Trial Radar · NCT02208154

Ecological Effects of Decolonisation Strategies in Intensive Care

RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care

Last checked: Nov 19, 2026Latest source record: Nov 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 8,665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,665

Actual

Start

Dec 1, 2013

Primary completion

Oct 27, 2017

Study completion Oct 27, 2017

Sponsor

Lead sponsor
MJM BontenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Paris 12 Val de Marne University
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Previous research has shown that applying certain treatments can reduce both the number of infections and the presence of resistant bacteria in the intensive care (ICU) and its patients. These treatments have been used as standard care throughout the world for many years, but they have not been compared to each other yet. The investigators aim to evaluate the effect of 3 different treatments on the occurrence of resistant bacteria and bacterial infections in the ICU and to establish which treatment is the best. All adult patients undergoing mechanical ventilation are eligible for this study and will receive treatment according to the study scheme. Twice weekly, sputum and rectal samples will be obtained to measure the effects. All ICU-patients will receive standard treatment, consisting of daily body washing with an antiseptic (chlorhexidine 2%), oral care and a hand-hygiene program for health care workers as endorsed by the WHO. According to 4 different study periods, each participant will receive one of the following extra treatments depending on his or her admission date: * Standard treatment only (this is the control group) * Chlorhexidine 1% oral gel, this is an antiseptic. * Antibiotic mouth paste containing 3 different antibiotics (selective oropharyngeal decontamination, SOD). * Antibiotic mouth paste and suspension for the stomach and intestines containing 3 different antibiotics (selective digestive decontamination, SDD). All treatments will be given 4 times daily with the purpose of killing harmful bacteria in the mouth (CHX, SOD,SDD) and digestive tract (SDD). During the study the investigators will examine the effect of these treatments on: * the occurrence of blood stream infections with certain bacteria * cross-transmission of certain bacteria between patients * presence of these bacteria in the respiratory tract of the patients * patient survival Benefits: Previous research has shown that these interventions can reduce infections in intensive care patients. Risks: The interventions performed (both cultures and treatment) are considered safe and are already given as standard care in many ICUs throughout the world. There is a slight risk that bacteria become resistant to antibiotics: this will be monitored closely during the trial.

Conditions

  • ICU-ecology (Multidrug Resistant Bacteria)
  • ICU-acquired Bacteraemia

Interventions

  • Chlorhexidine oral care (CHX-Oro)Drug

    Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.

  • Selective oropharyngeal decontamination (SOD)Drug

    SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.

  • Selective Digestive Decontamination (SDD)Drug

    SDD consists of both: * SOD (described elsewhere) * AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube. The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ICU-EcologyTime frame: 27 months

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Algemeen Ziekenhuis Sint Lucas

    Ghent, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • CHU Liege

    Liège, Belgium

  • Clinique Saint-Pierre Ottignies

    Ottignies, Belgium

  • Ospedale San Camillo

    Rome, Italy

  • Hospital Geral de Santo António (Centro Hospitalar do Porto, EPE)

    Porto, Portugal

  • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE

    Vila Real, Portugal

  • University clinic of respiratory and allergic diseases

    Golnik, Slovenia

  • Hospital Clinic of Barcelona

    Barcelona, Spain

  • l'Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario y Politécnico La Fé de Valencia

    Valencia, Spain

  • University Hospital of Wales

    Cardiff, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.